Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSLP | Q969D9 | 12/20 | 0.47 |
| ▸ | GRB7 | Q14451 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 3/20 | 0.44 |
| ▸ | MC5R | P33032 | 3/20 | 0.44 |
| ▸ | MC3R | P41968 | 3/20 | 0.44 |
| ▸ | MC1R | Q01726 | 3/20 | 0.44 |
| ▸ | CTSG | P08311 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | ITGAV | P06756 | 2/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.44 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10052624 | 1.00 | TSLP (0.47) | TSLPGRB7MC4RMC5RMC3R | |
| SCHEMBL10046409 | 1.00 | TSLP (0.47) | TSLPGRB7MC4RMC5RMC3R | |
| SCHEMBL22003312 | 1.00 | TSLP (0.47) | TSLPGRB7MC4RMC5RMC3R | |
| SCHEMBL12353621 | 0.94 | TSLP (0.50) | TSLPGRB7MC4RMC5RMC3R | |
| SCHEMBL13887745 | 0.94 | MC4R (0.44) | TSLPMC4RMC5RMC3RMC1R | |
| SCHEMBL16326787 | 0.92 | ITGB3 (0.45) | TSLPMC4RMC5RMC3RMC1R | |
| SCHEMBL16349760 | 0.92 | MC4R (0.47) | TSLPGRB7MC4RMC5RMC3R | |
| SCHEMBL13887996 | 0.91 | ITGB3 (0.49) | TSLPMC4RMC5RMC3RMC1R | |
| SCHEMBL20809940 | 0.91 | ITGB3 (0.49) | TSLPMC4RMC5RMC3RMC1R | |
| SCHEMBL12462751 | 0.91 | ITGB3 (0.49) | TSLPMC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723991-B2 | Radiopharmaceutical compositions | SERAC HEALTHCARE LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20210060189-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | SERAC HEALTHCARE LIMITED (GB) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723991-B2 | Radiopharmaceutical compositions | TYMP, KIT, CHEK1 | TSLP 329/4885GRB7 1916/4885MC4R 576/4885 |
| US-20210060189-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | TYMP, KIT, CHEK1 | TSLP 329/4885GRB7 1916/4885MC4R 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.